(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
Avaya (AVYA) shares slumped 23% after the company said it now expects fiscal Q3 revenue to range from $575 million to $580 million, lower than its...
Solid Biosciences (SLDB) has an average rating of outperform and price targets ranging from $2 to $12, according to analysts polled by Capital IQ. (MT...
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
Solid Biosciences (SLDB) has an average rating of outperform and price targets ranging from $2 to $12, according to analysts polled by Capital IQ. (MT...
Solid Biosciences (SLDB) said Monday it is working with Forge Biologics for the development and manufacturing of its SGT-003, which is intended for the...
Solid Biosciences (SLDB) reported additional positive pulmonary function data from the first six patients in a phase 1/2 clinical trial of SGT-001, a gene...
Solid Biosciences (SLDB) has an average outperform rating and a price target range of $2 to $17, according to analysts polled by Capital IQ. (MT Newswires...
Solid Biosciences (SLDB) said Thursday it will report "positive" data from a phase I/II trial of its drug SGT-001 to treat Duchenne muscular dystrophy. ...